NanoPhoria Bioscience Secures Funding to Advance Breakthrough Heart Failure Therapy & Expand Portfolio for Novel Nano-in-Micro Delivery Platform
NanoPhoria Bioscience recently announced the successful first close of its €83.5 million Series A financing round. The round was led by XGEN Venture, Sofinnova Partners, and CDP Venture Capital, with Panakes Partners also investing and one other undisclosed investor joining the round.
The funding will propel NanoPhoria’s lead candidate, NP-MP1, through IND-enabling studies and early clinical development. NP-MP1 is a first-in-class peptide that targets cardiac L-type calcium channels to improve ejection fraction for the treatment of heart failure with reduced ejection fraction (HFrEF).
Delivered via NanoPhoria’s proprietary lung-to-heart nano-in-micro technology, NP-MP1 has demonstrated excellent efficacy in preclinical models of heart failure and aims to address a root cause of HFrEF by improving cardiac contractility. HFrEF is a condition affecting millions globally with a five-year mortality rate of approximately 40%.
“This financing is a transformational milestone for NanoPhoria,” said Claudio De Luca, CEO and co-founder. “It enables us to accelerate clinical development of NP-MP1 and expand our pipeline. Our innovative delivery platform allows us to target previously inaccessible cellular targets in the cardiomyocyte, thereby bringing us closer to delivering life-changing treatments for patients living with serious cardiac and other chronic conditions who are underserved by existing treatments. We are profoundly grateful to our scientific founders, our investors, our Board, and our Chair, Suman Shirodkar, whose vision and efforts have shaped NanoPhoria’s progress and ambition.”
This investment perfectly aligns with XGEN’s strategy to lead early financing rounds in the most innovative Italian startups that address true medical needs,” said Paolo Fundarò, Managing Partner at XGEN Venture. “NanoPhoria’s science provides a novel, and viable, way of delivering highly potent therapeutics directly to the heart and we look forward to working alongside such a fantastic syndicate of investors.”
“NanoPhoria’s platform has the potential to redefine treatment paradigms in cardiovascular and other chronic diseaseswhich is why we are excited to invest in this company,” added Henrijette Richter, Managing Partner at Sofinnova Partners. “This financing builds on the early support of my colleague Lucia Faccio, Partner in the Sofinnova Telethon Strategy, whose role was instrumental in supporting the company in its early days to take shape. The investment reflects Sofinnova’s broader commitment to backing world-class science across Europe, from early-stage company creation to late-stage growth.”
Total Page Views: 853
